Prognosis for women with breast cancer not worse for those with family history
the ONA take:
A family history of breast cancer does not influence prognosis for women with breast cancer, according to results of a new large study from UK researchers. Approximately one-quarter of breast cancer cases in developed countries are thought to be hereditary.
The researchers conducted an analysis of the Prospective Outcomes in Sporadic versus Hereditary breast cancer (POSH) study, which included 2,850 women younger than 41 years with a breast cancer diagnosis and were treated in the United Kingdom.
POSH investigators had recorded information on patients’ tumors, treatment, family history of breast/ovarian cancer, and personal characteristics over a 15-year period.
In this study, no significant differences were found in cancer recurrence rates between women with a family history and those with no family history.
Future investigations will focus on the impact of certain gene variants on the effectiveness of different anticancer treatments.
A family history of breast cancer does not influence prognosis for women with breast cancer.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Prolactin Expression May Indicate Better Prognosis for Patients With TNBC
- Caregiver Mastery Linked to Patient Survival in Glioblastoma
- Treatment Facility Volume Associated With Mortality Risk in Multiple Myeloma
- Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|